Summary of medicine characteristics - Xolair
1. NAME OF THE MEDICINAL PRODUCT
Xolair 150 mg powder and solvent for solution for injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One vial contains 150 mg of omalizumab*.
After reconstitution one vial contains 125 mg/ml of omalizumab (150 mg in 1.2 ml).
*Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell line.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Powder and solvent for solution for injection.
Powder: white to off-white lyophilisate
Solvent: clear and colourless solution
4. CLINICAL PARTICULARS4.1 Therapeutic indications
Allergic asthma
Xolair is indicated in adults, adolescents and children (6 to <12 years of age).
Xolair treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2).
Adults and adolescents (12 years of age and older)
Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 <80%) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily highdose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.
Children (6 to <12 years of age)
Xolair is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Xolair is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control.
Chronic spontaneous urticaria (CSU)
Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.
4.2 Posology and method of administration
Xolair treatment should be initiated by physicians experienced in the diagnosis and treatment of severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) or chronic spontaneous urticaria.
Posology
Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
Dosing for allergic asthma and CRSwNP follows the same dosing principles. The appropriate dose and frequency of Xolair for these conditions is determined by baseline IgE (IU/ml), measured before the start of treatment, and body weight (kg). Prior to administration of the initial dose, patients should have their IgE level determined by any commercial serum total IgE assay for their dose assignment. Based on these measurements, 75 to 600 mg of Xolair in 1 to 4 injections may be needed for each administration.
Allergic asthma patients with baseline IgE lower than 76 IU/ml were less likely to experience benefit (see section 5.1). Prescribing physicians should ensure that adult and adolescent patients with IgE below 76 IU/ml and children (6 to < 12 years of age) with IgE below 200 IU/ml have unequivocal in vitro reactivity (RAST) to a perennial allergen before starting therapy.
See Table 1 for a conversion chart and Tables 2 and 3 for the dose determination charts.
Patients whose baseline IgE levels or body weight in kilograms are outside the limits of the dose table should not be given Xolair.
The maximum recommended dose is 600 mg omalizumab every two weeks.
Table 1 Conversion from dose to number of vials, number of injections and total injection volume for each administration
| Dose (mg) | Number of vials | Number of injections | Total injection volume (ml) | |
| 75 mg a | 150 mg b | |||
| 75 | 1c | 0 | 1 | 0.6 |
| 150 | 0 | 1 | 1 | 1.2 |
| 225 | 1c | 1 | 2 | 1.8 |
| 300 | 0 | 2 | 2 | 2.4 |
| 375 | 1c | 2 | 3 | 3.0 |
| 450 | 0 | 3 | 3 | 3.6 |
| 525 | 1c | 3 | 4 | 4.2 |
| 600 | 0 | 4 | 4 | 4.8 |
a 0.6 ml = maximum delivered volume per vial (Xolair 75 mg).
b 1.2 ml = maximum delivered volume per vial (Xolair 150 mg).
or use 0.6 ml from a 150 mg vial.
Table 2 ADMINISTRATION EVERY 4 WEEKS. Xolair doses (milligrams per dose) administered by subcutaneous injection every 4 weeks
| Body weight (kg) | |
| Baseline IgE (IU/ml) | >20– >25– >30– >40– >50– >60– >70– >80– >90– >125– 25* 30* 40 50 60 70 80 90 125 150 |
| >30–100 >100–200 >200–300 >300–400 >400–500 >500–600 >600–700 >700–800 >800–900 >900–1000 >1000–1100 | 75 75 75 150 150 150 150 150 300 300 150 150 150 300 300 300 300 300 450 600 150 150 225 300 300 450 450 450 600 225 225 300 450 450 450 600 600 |
| 225 300 450 450 600 600 300 300 450 600 600 300 450 600 ADMINISTRATION EVERY 2 WEEKS SEE TABLE 3 |
Body weights below 30 kg were not studied in the pivotal trials for CRSwNP.
Table 3 ADMINSTRATION EVERY 2 WEEKS. Xolair doses (milligrams per dose) administered by subcutaneous injection every 2 weeks
| Body weight (kg) | ||||||||||
| Baseline IgE (IU/ml) | >20–25 | >25–30* | >30– 40 | >40– 50 | >50– 60 | >60– 70 | >70– 80 | >80– 90 | >90– 125 | >125– 150 |
| >30–100 >100–200 | ADMINISTRATION EVERY 4 WEEKS SEE TABLE 2 | |||||||||
| >200–300 | 375 | |||||||||
| >300–400 | 450 | 525 | ||||||||
| >400–500 | 375 | 375 | 525 | 600 | ||||||
| >500–600 | 375 | 450 | 450 | 600 | ||||||
| >600–700 | 225 | 375 | 450 | 450 | 525 | |||||
| >700–800 | 225 | 225 | 300 | 375 | 450 | 450 | 525 | 600 | ||
| >800–900 | 225 | 225 | 300 | 375 | 450 | 525 | 600 | |||
| >900–1000 | 225 | 300 | 375 | 450 | 525 | 600 | ||||
| >1000–1100 >1100– 1200 | 225 300 | 300 300 | 375 450 | 450 525 | 600 600 | Insufficient data to recommend a dose | ||||
| >1200–1300 >1300– 1500 | 300 300 | 375 375 | 450 525 | 525 600 | ||||||
*Body weights below 30 kg were not studied in the pivotal trials for CRSwNP.
Treatment duration, monitoring and dose adjustments
Allergic asthma
Xolair is intended for long-term treatment. Clinical trials have demonstrated that it takes at least 12–16 weeks for Xolair treatment to show effectiveness. At 16 weeks after commencing Xolair therapy patients should be assessed by their physician for treatment effectiveness before further injections are administered. The decision to continue Xolair following the 16-week timepoint, or on subsequent occasions, should be based on whether a marked improvement in overall asthma control is seen (see section 5.1, Physician’s overall assessment of treatment effectiveness).
Chronic rhinosinusitis with nasal polyps (CRSwNP)
In clinical trials for CRSwNP, changes in nasal polyps score (NPS) and nasal congestion score (NCS) were observed at 4 weeks. The need for continued therapy should be periodically reassessed based upon the patient’s disease severity and level of symptom control.
Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
Discontinuation of Xolair treatment generally results in a return to elevated free IgE levels and associated symptoms. Total IgE levels are elevated during treatment and remain elevated for up to one year after the discontinuation of treatment. Therefore, re-testing of IgE levels during Xolair treatment cannot be used as a guide for dose determination. Dose determination after treatment interruptions lasting less than one year should be based on serum IgE levels obtained at the initial dose determination. Total serum IgE levels may be re-tested for dose determination if treatment with Xolair has been interrupted for one year or more.
Doses should be adjusted for significant changes in body weight (see Tables 2 and 3).
Chronic spontaneous urticaria (CSU)
The recommended dose is 300 mg by subcutaneous injection every four weeks.
Prescribers are advised to periodically reassess the need for continued therapy.
Clinical trial experience of long-term treatment beyond 6 months in this indication is limited.
Special populations
Elderly (65 years of age and older)
There are limited data available on the use of Xolair in patients older than 65 years but there is no evidence that elderly patients require a different dose from younger adult patients.
Renal or hepatic impairment
There have been no studies on the effect of impaired renal or hepatic function on the pharmacokinetics of omalizumab. Because omalizumab clearance at clinical doses is dominated by the reticular endothelial system (RES) it is unlikely to be altered by renal or hepatic impairment. While no particular dose adjustment is recommended for these patients, Xolair should be administered with caution (see section 4.4).
Paediatric population
In allergic asthma, the safety and efficacy of Xolair in patients below the age of 6 years have not been established. No data are available.
In CRSwNP, the safety and efficacy of Xolair in patients below the age of 18 years have not been established.
In CSU, the safety and efficacy of Xolair in patients below the age of 12 years have not been established.
Method of administration
For subcutaneous administration only. Xolair must not be administered by the intravenous or intramuscular route.
Doses of more than 150 mg (Table 1) should be divided across two or more injection sites.
There is limited experience with self-administration of Xolair powder and solvent for solution for injection. Therefore, treatment with this formulation is intended to be administered by a healthcare provider only.
For instructions on reconstitution of the medicinal product before administration, see section 6.6 and also information for the healthcare professional section of the package leaflet.
4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
4.4 Special warnings and precautions for use
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
General
Xolair is not indicated for the treatment of acute asthma exacerbations, acute bronchospasm or status asthmaticus.
Xolair has not been studied in patients with hyperimmunoglobulin E syndrome or allergic bronchopulmonary aspergillosis or for the prevention of anaphylactic reactions, including those provoked by food allergy, atopic dermatitis, or allergic rhinitis. Xolair is not indicated for the treatment of these conditions.
Xolair therapy has not been studied in patients with autoimmune diseases, immune complex-mediated conditions, or pre-existing renal or hepatic impairment (see section 4.2). Caution should be exercised when administering Xolair in these patient populations.
Abrupt discontinuation of systemic or inhaled corticosteroids after initiation of Xolair therapy in allergic asthma or CRSwNP is not recommended. Decreases in corticosteroids should be performed under the direct supervision of a physician and may need to be performed gradually.
Immune system disorders
Allergic reactions type I
Type I local or systemic allergic reactions, including anaphylaxis and anaphylactic shock, may occur when taking omalizumab, even after a long duration of treatment. However, most of these reactions occurred within 2 hours after the first and subsequent injections of Xolair but some started beyond 2 hours and even beyond 24 hours after the injection. The majority of anaphylactic reactions occurred within the first 3 doses of Xolair. A history of anaphylaxis unrelated to omalizumab may be a risk factor for anaphylaxis following Xolair administration. Therefore medicinal products for the treatment of anaphylactic reactions should always be available for immediate use following administration of Xolair. If an anaphylactic or other serious allergic reaction occurs, administration of Xolair must be discontinued immediately, and appropriate therapy initiated. Patients should be informed that such reactions are possible, and prompt medical attention should be sought if allergic reactions occur.
Antibodies to omalizumab have been detected in a low number of patients in clinical trials (see section 4.8). The clinical relevance of anti-Xolair antibodies is not well understood.
Serum sickness
Serum sickness and serum sickness-like reactions, which are delayed allergic type III reactions, have been seen in patients treated with humanised monoclonal antibodies including omalizumab. The suggested pathophysiologic mechanism includes immune-complex formation and deposition due to development of antibodies against omalizumab. The onset has typically been 1–5 days after administration of the first or subsequent injections, also after long duration of treatment. Symptoms suggestive of serum sickness include arthritis/arthralgias, rash (urticaria or other forms), fever and lymphadenopathy. Antihistamines and corticosteroids may be useful for preventing or treating this disorder, and patients should be advised to report any suspected symptoms.
Churg-Strauss syndrome and hypereosinophilic syndrome
Patients with severe asthma may rarely present systemic hypereosinophilic syndrome or allergic eosinophilic granulomatous vasculitis (Churg-Strauss syndrome), both of which are usually treated with systemic corticosteroids.
In rare cases, patients on therapy with anti-asthma medicinal products, including omalizumab, may present or develop systemic eosinophilia and vasculitis. These events are commonly associated with the reduction of oral corticosteroid therapy.
In these patients, physicians should be alert to the development of marked eosinophilia, vasculitic rash, worsening pulmonary symptoms, paranasal sinus abnormalities, cardiac complications, and/or neuropathy.
Discontinuation of omalizumab should be considered in all severe cases with the above mentioned immune system disorders.
Parasitic (helminth) infections
IgE may be involved in the immunological response to some helminth infections. In patients at chronic high risk of helminth infection, a placebo-controlled trial in allergic patients showed a slight increase in infection rate with omalizumab, although the course, severity, and response to treatment of infection were unaltered. The helminth infection rate in the overall clinical programme, which was not designed to detect such infections, was less than 1 in 1,000 patients. However, caution may be warranted in patients at high risk of helminth infection, in particular when travelling to areas where helminthic infections are endemic. If patients do not respond to recommended anti-helminth treatment, discontinuation of Xolair should be considered.
4.5 Interaction with other medicinal products and other forms of interaction
Since IgE may be involved in the immunological response to some helmith infections, Xolair may indirectly reduce the efficacy of medicinal products for the treatment of helminthic or other parasitic infections (see section 4.4).
Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the clearance of omalizumab; thus, there is little potential for drug-drug interactions. Medicinal product or vaccine interaction studies have not been performed with Xolair. There is no pharmacological reason to expect that commonly prescribed medicinal products used in the treatment of asthma, CRSwNP or CSU will interact with omalizumab.
Allergic asthma
In clinical studies Xolair was commonly used in conjunction with inhaled and oral corticosteroids, inhaled short-acting and long-acting beta agonists, leukotriene modifiers, theophyllines and oral antihistamines. There was no indication that the safety of Xolair was altered with these other commonly used anti-asthma medicinal products. Limited data are available on the use of Xolair in combination with specific immunotherapy (hypo-sensitisation therapy). In a clinical trial where Xolair was co-administered with immunotherapy, the safety and efficacy of Xolair in combination with specific immunotherapy were found to be no different to that of Xolair alone.
Chronic rhinosinusitis with nasal polyps (CRSwNP)
In clinical studies Xolair was used in conjunction with intranasal mometasone spray as per protocol. Other commonly used concomitant medicinal products included other intranasal corticosteroids, bronchodilators, antihistamines, leukotriene receptor antagonists, adrenergics/sympathomimetics and local nasal anaesthetics. There was no indication that the safety of Xolair was altered by the concomitant use of these other commonly used medicinal products.
Chronic spontaneous urticaria (CSU)
In clinical studies in CSU, Xolair was used in conjunction with antihistamines (anti-H1, anti-H2) and leukotriene receptor antagonists (LTRAs). There was no evidence that the safety of omalizumab was altered when used with these medicinal products relative to its known safety profile in allergic asthma. In addition, a population pharmacokinetic analysis showed no relevant effect of H2 antihistamines and LTRAs on omalizumab pharmacokinetics (see section 5.2).
Paediatric population
Clinical studies in CSU included some patients aged 12 to 17 years taking Xolair in conjunction with antihistamines (anti-H1, anti-H2) and LTRAs. No studies have been performed in children under 12 years.
4.6 Fertility, pregnancy and lactation
Pregnancy
A moderate amount of data on pregnant women (between 300–1,000 pregnancy outcomes) based on pregnancy registry and post-marketing spontaneous reports, indicates no malformative or foeto/neonatal toxicity. A prospective pregnancy registry study (EXPECT) in 250 pregnant women with asthma exposed to Xolair showed the prevalence of major congenital anomalies was similar (8.1% vs. 8.9%) between EXPECT and disease-matched (moderate and severe asthma) patients. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and non-randomised design.
Omalizumab crosses the placental barrier. However, animal studies do not indicate either direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).
Omalizumab has been associated with age-dependent decreases in blood platelets in non-human primates, with a greater relative sensitivity in juvenile animals (see section 5.3).
If clinically needed, the use of Xolair may be considered during pregnancy.
Breast-feeding
Immunoglobulins G (IgGs) are present in human milk and therefore it is expected that omalizumab will be present in human milk. Available data in non-human primates have shown excretion of omalizumab into milk (see section 5.3).
The EXPECT study, with 154 infants who had been exposed to Xolair during pregnancy and through breast-feeding did not indicate adverse effects on the breast-fed infant. The interpretation of data may be impacted due to methodological limitations of the study, including small sample size and nonrandomised design.
Given orally, immunoglobulin G proteins undergo intestinal proteolysis and have poor bioavailability. No effects on the breast-fed newborns/infants are anticipated. Consequently, if clinically needed, the use of Xolair may be considered during breast-feeding.
Fertility
There are no human fertility data for omalizumab. In specifically-designed non-clinical fertility studies, in non-human primates including mating studies, no impairment of male or female fertility was observed following repeated dosing with omalizumab at dose levels up to 75 mg/kg. Furthermore, no genotoxic effects were observed in a separate non-clinical genotoxicity study.
4.7 Effects on ability to drive and use machines
Xolair has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
Summary of safety profile
During allergic asthma clinical trials in adult and adolescent patients 12 years of age and older, the most commonly reported adverse reactions were headaches and injection site reactions, including injection site pain, swelling, erythema and pruritus. In clinical trials in children 6 to <12 years of age, the most commonly reported adverse reactions were headache, pyrexia and upper abdominal pain. Most of the reactions were mild or moderate in severity. In clinical trials in patients >18 years of age in CRSwNP, the most commonly reported adverse reactions were headache, dizziness, arthralgia, abdominal pain upper and injection site reactions.
Tabulated list of adverse reactions
Table 4 lists the adverse reactions recorded in clinical studies in the total allergic asthma and CRSwNP safety population treated with Xolair by MedDRA system organ class and frequency. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. Frequency categories are defined as: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000) and very rare (<1/10,000). Reactions reported in the postmarketing setting are listed with frequency not known (cannot be estimated from the available data).
Table 4 Adverse reactions in allergic asthma and CRSwNP
| Infections and infestations | |
| Uncommon Rare | Pharyngitis Parasitic infection |
| Blood and lymphatic system disorders | |
| Not known | Idiopathic thrombocytopenia, including severe cases |
| Immune system disorders | |
| Rare Not known | Anaphylactic reaction, other serious allergic conditions, anti-omalizumab antibody development Serum sickness, may include fever and lymphadenopathy |
| Nervous system disorders | |
| Common Uncommon | Headache* Syncope, paraesthesia, somnolence, dizziness# |
| Vascular disorders | |
| Uncommon | Postural hypotension, flushing |
| Respiratory, thoracic and mediastinal disorders | |
| Uncommon Rare Not known | Allergic bronchospasm, coughing Laryngoedema Allergic granulomatous vasculitis (i.e. Churg-Strauss syndrome) |
| Gastrointestinal disorders | |
| Common Uncommon | Abdominal pain upper,# Dyspeptic signs and symptoms, diarrhoea, nausea |
| Skin and subcutaneous tissue disorders | |
| Uncommon Rare Not known | Photosensitivity, urticaria, rash, pruritus Angioedema Alopecia |
| Musculoskeletal and connective tissue disorders | |
| Common Rare Not known | Athralgiaf Systemic lupus erythematosus (SLE) Myalgia, joint swelling |
| General disorders and administration site conditions | |
| Very common Common Uncommon | Pyrexia Injection site reactions such as swelling, erythema, pain, pruritus Influenza-like illness, swelling arms, weight increase, fatigue |
: Very common in children 6 to <12 years of age
**: In children 6 to <12 years of age
#: Common in nasal polyp trials
f: Unknown in allergic asthma trials
Chronic spontaneous urticaria (CSU)
Summary of safety profile
The safety and tolerability of omalizumab were investigated with doses of 75 mg, 150 mg and 300 mg every four weeks in 975 CSU patients, 242 of whom received placebo. Overall, 733 patients were treated with omalizumab for up to 12 weeks and 490 patients for up to 24 weeks. Of those, 412 patients were treated for up to 12 weeks and 333 patients were treated for up to 24 weeks at the 300 mg dose.
Tabulated list of adverse reactions
A separate table (Table 5) shows the adverse reactions for the CSU indication resulting from differences in dosages and treatment populations (with significantly different risk factors, comorbidities, co-medications and ages [e.g. asthma trials included children from 6–12 years of age]).
Table 5 lists the adverse reactions (events occurring in >1% of patients in any treatment group and >2% more frequently in any omalizumab treatment group than with placebo (after medical review)) reported with 300 mg in the three pooled phase III studies. The adverse reactions presented are divided into two groups: those identified in the 12-week and the 24-week treatment periods.
The adverse reactions are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions listed first. The corresponding frequency category for each adverse reaction is based on the following convention: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1000); very rare (<1/10,000) and not known (cannot be estimated from the available data).
Table 5 Adverse reactions from the pooled CSU safety database (day 1 to week 24) at 300 mg omalizumab
| 12-Week — | Omalizumab studies 1, 2 and 3 Pooled | Frequency category | |
| Placebo N=242 | 300 mg N=412 | ||
| Infections and infestations Sinusitis | 5 (2.1%) | 20 (4.9%) | Common |
| Nervous system disorders Headache | 7 (2.9%) | 25 (6.1%) | Common |
| Musculoskeletal and connective tissue disorders | |||
| Arthralgia | 1 (0.4%) | 12 (2.9%) | Common |
| General disorder and administration site conditions | |||
| Injection site reaction | 2 (0.8%) | 11 (2.7%) | Common |
| Omalizumab studies 1 and 3 Pooled | Frequency category | ||
| 24-week | Placebo N=163 | 300 mg N=333 | |
| Infections and infestations Upper respiratory tract infection | 5 (3.1%) | 19 (5.7%) | Common |
* Despite not showing a 2% difference to placebo, injection site reactions were included as all cases were assessed causally related to study treatment.
Description of selected adverse reactions
Immune system disorders
For further information, see section 4.4.
Anaphylaxis
Anaphylactic reactions were rare in clinical trials. However, post-marketing data following a cumulative search in the safety database retrieved a total of 898 anaphylaxis cases. Based on an estimated exposure of 566,923 patient treatment years, this results in a reporting rate of approximately 0.20%.
Arterial thromboembolic events (ATE)
In controlled clinical trials and during interim analyses of an observational study, a numerical imbalance of ATE was observed. The definition of the composite endpoint ATE included stroke, transient ischaemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause). In the final analysis of the observational study, the rate of ATE per 1,000 patient years was 7.52 (115/15,286 patient years) for Xolair-treated patients and 5.12 (51/9,963 patient years) for control patients. In a multivariate analysis controlling for available baseline cardiovascular risk factors, the hazard ratio was 1.32 (95% confidence interval 0.91–1.91). In a separate analysis of pooled clinical trials, which included all randomised double-blind, placebo-controlled clinical trials lasting 8 or more weeks, the rate of ATE per 1,000 patient years was 2.69 (5/1,856 patient years) for Xolair-treated patients and 2.38 (4/1,680 patient years) for placebo patients (rate ratio 1.13, 95% confidence interval 0.24–5.71).
Platelets
In clinical trials few patients had platelet counts below the lower limit of the normal laboratory range. None of these changes were associated with bleeding episodes or a decrease in haemoglobin. No pattern of persistent decrease in platelet counts, as observed in non-human primates (see section 5.3), has been reported in humans (patients above 6 years of age), even though isolated cases of idiopathic thrombocytopenia, including severe cases, have been reported in the post-marketing setting.
Parasitic infections
In allergic patients at chronic high risk of helminth infection, a placebo-controlled trial showed a slight numerical increase in infection rate with omalizumab that was not statistically significant. The course, severity, and response to treatment of infections were unaltered (see section 4.4).
Systemic lupus erythematosus
Clinical trial and post-marketing cases of systemic lupus erythematosus (SLE) have been reported in patients with moderate to severe asthma and CSU. The pathogenesis of SLE is not well understood.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in
4.9 Overdose
Maximum tolerated dose of Xolair has not been determined. Single intravenous doses up to 4,000 mg have been administered to patients without evidence of dose-limiting toxicities. The highest cumulative dose administered to patients was 44,000 mg over a 20-week period and this dose did not result in any untoward acute effects.
If an overdose is suspected, the patient should be monitored for any abnormal signs or symptoms. Medical treatment should be sought and instituted appropriately.
5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Drugs for obstructive airway diseases, other systemic drugs for obstructive airway diseases, ATC code: R03DX05
Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE). The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE.
Allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
Mechanism of action
Omalizumab binds to IgE and prevents binding of IgE to FcsRI (high-affinity IgE receptor) on basophils and mast cells, thereby reducing the amount of free IgE that is available to trigger the allergic cascade. Treatment of atopic subjects with omalizumab resulted in a marked down-regulation of FcsRI receptors on basophils. Treatment with Xolair inhibits IgE-mediated inflammation, as evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, including IL-4, IL-5, and IL-13 by innate, adaptive and non-immune cells.
Pharmacodynamic effects
Allergic asthma
The in vitro histamine release from basophils isolated from Xolair-treated subjects was reduced by approximately 90% following stimulation with an allergen compared to pre-treatment values.
In clinical studies in allergic asthma patients, serum free IgE levels were reduced in a dose-dependent manner within one hour following the first dose and maintained between doses. One year after discontinuation of Xolair dosing, the IgE levels had returned to pre-treatment levels with no observed rebound in IgE levels after washout of the medicinal product.
Chronic rhinosinusitis with nasal polyps (CRSwNP)
In clinical studies in patients with CRSwNP, Xolair treatment led to a reduction in serum free IgE (approx. 95%) and an increase in serum total IgE levels, to a similar extent as observed in patients with allergic asthma. Total IgE levels in serum increased due to the formation of omalizumab-IgE complexes that have a slower elimination rate compared with free IgE.
Chronic spontaneous urticaria (CSU)
Mechanism of action
Omalizumab binds to IgE and lowers free IgE levels. Subsequently, IgE receptors (FcsRI) on cells down-regulate. It is not entirely understood how this results in an improvement of CSU symptoms.
Pharmacodynamic effect
In clinical studies in CSU patients, maximum suppression of free IgE was observed 3 days after the first subcutaneous dose. After repeated dosing once every 4 weeks, pre-dose serum free IgE levels remained stable between 12 and 24 weeks of treatment. After discontinuation of Xolair, free IgE levels increased towards pre-treatment levels over a 16-week treatment-free follow-up period.
Clinical efficacy and safety
Allergic asthma
Adults and adolescents >12 years of age
The efficacy and safety of Xolair were demonstrated in a 28-week double-blind placebo-controlled study (study 1) involving 419 severe allergic asthmatics, ages 12–79 years, who had reduced lung function (FEV1 40–80% predicted) and poor asthma symptom control despite receiving high dose inhaled corticosteroids and a long-acting beta2-agonist. Eligible patients had experienced multiple asthma exacerbations requiring systemic corticosteroid treatment or had been hospitalised or attended an emergency room due to a severe asthma exacerbation in the past year despite continuous treatment with high-dose inhaled corticosteroids and a long-acting beta2-agonist. Subcutaneous Xolair or placebo were administered as add-on therapy to >1,000 micrograms beclomethasone dipropionate (or equivalent) plus a long-acting beta2-agonist. Oral corticosteroid, theophylline and leukotrienemodifier maintenance therapies were allowed (22%, 27%, and 35% of patients, respectively).
The rate of asthma exacerbations requiring treatment with bursts of systemic corticosteroids was the primary endpoint. Omalizumab reduced the rate of asthma exacerbations by 19% (p = 0.153). Further evaluations which did show statistical significance (p<0.05) in favour of Xolair included reductions in severe exacerbations (where patient’s lung function was reduced to below 60% of personal best and requiring systemic corticosteroids) and asthma-related emergency visits (comprised of hospitalisations, emergency room, and unscheduled doctor visits), and improvements in Physician’s overall assessment of treatment effectiveness, Asthma-related Quality of Life (AQL), asthma symptoms and lung function.
In a subgroup analysis, patients with pre-treatment total IgE >76 IU/ml were more likely to experience clinically meaningful benefit to Xolair. In these patients in study 1 Xolair reduced the rate of asthma exacerbations by 40% (p = 0.002). In addition more patients had clinically meaningful responses in the total IgE >76 IU/ml population across the Xolair severe asthma programme. Table 6 includes results in the study 1 population.
Table 6 Results of study 1
| Whole study 1 | ||
| population | ||
| Xolair | Placebo | |
| N=209 | N=210 | |
| Asthma exacerbations Rate per 28-week period | 0.74 | 0.92 |
| % reduction, p-value for rate ratio | 19.4%, p = 0.153 | |
| Severe asthma exacerbations Rate per 28-week period | 0.24 | 0.48 |
| % reduction, p-value for rate ratio | 50.1%, p = 0.002 | |
| Emergency visits Rate per 28-week period | 0.24 | 0.43 |
| % reduction, p-value for rate ratio | 43.9%, p = 0.038 | |
| Physician’s overall assessment % responders* | 60.5% | 42.8% |
| p-value** | <0.001 | |
| AQL improvement % of patients >0.5 improvement | 60.8% | 47.8% |
| p-value | 0.008 | |
| ||
Study 2 assessed the efficacy and safety of Xolair in a population of 312 severe allergic asthmatics which matched the population in study 1. Treatment with Xolair in this open label study led to a 61% reduction in clinically significant asthma exacerbation rate compared to current asthma therapy alone.
Four additional large placebo-controlled supportive studies of 28 to 52 weeks duration in 1,722 adults and adolescents (studies 3, 4, 5, 6) assessed the efficacy and safety of Xolair in patients with severe persistent asthma. Most patients were inadequately controlled but were receiving less concomitant asthma therapy than patients in studies 1 or 2. Studies 3–5 used exacerbation as primary endpoint, whereas study 6 primarily evaluated inhaled corticosteroid sparing.
In studies 3, 4 and 5 patients treated with Xolair had respective reductions in asthma exacerbation rates of 37.5% (p = 0.027), 40.3% (p<0.001) and 57.6% (p<0.001) compared to placebo.
In study 6, significantly more severe allergic asthma patients on Xolair were able to reduce their fluticasone dose to <500 micrograms/day without deterioration of asthma control (60.3%) compared to the placebo group (45.8%, p<0.05).
Quality of life scores were measured using the Juniper Asthma-related Quality of Life Questionnaire. For all six studies there was a statistically significant improvement from baseline in quality of life scores for Xolair patients versus the placebo or control group.
Physician’s overall assessment of treatment effectiveness:
Physician’s overall assessment was performed in five of the above studies as a broad measure of asthma control performed by the treating physician. The physician was able to take into account PEF (peak expiratory flow), day and night time symptoms, rescue medication use, spirometry and exacerbations. In all five studies a significantly greater proportion of Xolair treated patients were judged to have achieved either a marked improvement or complete control of their asthma compared to placebo patients.
Children 6 to <12 years of age
The primary support for safety and efficacy of Xolair in the group aged 6 to <12 years comes from one randomised, double-blind, placebo-controlled, multi-centre trial (study 7).
Study 7 was a placebo-controlled trial which included a specific subgroup (n=235) of patients as defined in the present indication, who were treated with high-dose inhaled corticosteroids (>500 ^g/day fluticasone equivalent) plus long-acting beta agonist.
A clinically significant exacerbation was defined as a worsening of asthma symptoms as judged clinically by the investigator, requiring doubling of the baseline inhaled corticosteroid dose for at least 3 days and/or treatment with rescue systemic (oral or intravenous) corticosteroids for at least 3 days.
In the specific subgroup of patients on high dose inhaled corticosteroids, the omalizumab group had a statistically significantly lower rate of clinically significant asthma exacerbations than the placebo group. At 24 weeks, the difference in rates between treatment groups represented a 34% (rate ratio 0.662, p = 0.047) decrease relative to placebo for omalizumab patients. In the second double-blind 28-week treatment period the difference in rates between treatment groups represented a 63% (rate ratio 0.37, p<0.001) decrease relative to placebo for omalizumab patients.
During the 52-week double-blind treatment period (including the 24-week fixed-dose steroid phase and the 28-week steroid adjustment phase) the difference in rates between treatment groups represented a 50% (rate ratio 0.504, p<0.001) relative decrease in exacerbations for omalizumab patients.
The omalizumab group showed greater decreases in beta-agonist rescue medication use than the placebo group at the end of the 52-week treatment period, although the difference between treatment groups was not statistically significant. For the global evaluation of treatment effectiveness at the end of the 52-week double-blind treatment period in the subgroup of severe patients on high-dose inhaled corticosteroids plus long-acting beta agonists, the proportion of patients rated as having ‘excellent’ treatment effectiveness was higher, and the proportions having ‘moderate’ or ‘poor’ treatment effectiveness lower in the omalizumab group compared to the placebo group; the difference between groups was statistically significant (p<0.001), while there were no differences between the omalizumab and placebo groups for patients’ subjective Quality of Life ratings.
Chronic rhinosinusitis with nasal polyps (CRSwNP)
The safety and efficacy of Xolair were evaluated in two randomised, double-blind, placebo-controlled trials in patients with CRSwNP (Table 8). Patients received Xolair or placebo subcutaneously every 2 or 4 weeks (see section 4.2). All patients received background intranasal mometasone therapy throughout the study. Prior sino-nasal surgery or prior systemic corticosteroid usage were not required for inclusion in the studies. Patients received Xolair or placebo for 24 weeks followed by a 4-week follow-up period. Demographics and baseline characteristics, including allergic comorbidities, are described in Table 7.
Table 7 Demographics and baseline characteristics of nasal polyp studies
| Parameter | Nasal polyp study 1 N=138 | Nasal polyp study 2 N=127 |
| Mean age (years) (SD) | 51.0 (13.2) | 50.1 (11.9) |
| % Male | 63.8 | 65.4 |
| Patients with systemic corticosteroid use in the previous year (%) | 18.8 | 26.0 |
| Bilateral endoscopic nasal polyp score (NPS): mean (SD), range 0–8 | 6.2 (1.0) | 6.3 (0.9) |
| Nasal congestion score (NCS): mean (SD), range 0–3 | 2.4 (0.6) | 2.3 (0.7) |
| Sense of smell score: mean (SD), range 0–3 | 2.7 (0.7) | 2.7 (0.7) |
| SNOT-22 total score: mean (SD) range 0–110 | 60.1 (17.7) | 59.5 (19.3) |
| Blood eosinophils (cells/^l): mean (SD) | 346.1 (284.1) | 334.6 (187.6) |
| Total IgE lU/ml: mean (SD) | 160.9 (139.6) | 190.2 (200.5) |
| Asthma (%) | 53.6 | 60.6 |
| Mild (%) | 37.8 | 32.5 |
| Moderate (%) | 58.1 | 58.4 |
| Severe (%) | 4.1 | 9.1 |
| Aspirin exacerbated respiratory disease (%) | 19.6 | 35.4 |
| Allergic rhinitis | 43.5 | 42.5 |
SD = standard deviation; SNOT-22 = Sino-Nasal Outcome Test 22 Questionnaire; IgE = Immunoglobulin E; IU = international units. For NPS, NCS, and SNOT-22 higher scores indicate greater disease severity.
The co-primary endpoints were bilateral nasal polyps score (NPS) and average daily nasal congestion score (NCS) at Week 24. In both nasal polyp studies 1 and 2, patients who received Xolair had statistically significant greater improvements from baseline at Week 24 in NPS and weekly average NCS than patients who received placebo. Results from nasal polyp studies 1 and 2 are shown in Table 8.
Table 8 Change from baseline at Week 24 in clinical scores from nasal polyp study 1, nasal polyp study 2, and pooled data
| Nasal polyp study 1 | Nasal polyp study 2 | Nasal polyp pooled results | |
| Placebo Xolair | Placebo Xolair | Placebo Xolair | |
| N | 66 72 | 65 62 | 131 134 |
| Nasal polyp score | |||
| Baseline mean LS mean change at Week 24 | 6.32 6.19 0.06 -1.08 | 6.09 6.44 –0.31 -0.90 | 6.21 6.31 –0.13 -0.99 |
| Difference (95%) CI p-value | –1.14 (-1.59, –0.69) <0.0001 | –0.59 (-1.05, –0.12) 0.0140 | –0.86 (-1.18, –0.54) <0.0001 |
| 7-day average of daily nasal congestion score | |||
| Baseline mean LS mean change at Week 24 | 2.46 2.40 –0.35 -0.89 | 2.29 2.26 –0.20 -0.70 | 2.38 2.34 –0.28 -0.80 |
| Difference (95%) CI p-value | –0.55 (-0.84, –0.25) 0.0004 | –0.50 (-0.80, –0.19) 0.0017 | –0.52 (-0.73, –0.31) <0.0001 |
| TNSS | |||
| Baseline mean LS mean change at Week 24 | 9.33 8.56 –1.06 -2.97 | 8.73 8.37 –0.44 -2.53 | 9.03 8.47 –0.77 -2.75 |
| Difference (95%) p-value | –1.91 (-2.85, –0.96) 0.0001 | –2.09 (-3.00, –1.18) <0.0001 | –1.98 (-2.63, –1.33) <0.0001 |
| SNOT-22 | |||
| Baseline mean LS mean change at Week 24 | 60.26 59.82 –8.58 -24.70 | 59.80 59.21 –6.55 -21.59 | 60.03 59.54 –7.73 -23.10 |
| Difference (95%) p-value (MID = 8.9) | –16.12 (-21.86, –10.38) <0.0001 | –15.04 (-21.26, –8.82) <0.0001 | –15.36 (-19.57, –11.16) <0.0001 |
| UPSIT | |||
| Baseline mean LS mean change at Week 24 | 13.56 12.78 0.63 4.44 | 13.27 12.87 0.44 4.31 | 13.41 12.82 0.54 4.38 |
| Difference (95%) p-value | 3.81 (1.38, 6.24) 0.0024 | 3.86 (1.57, 6.15) 0.0011 | 3.84 (2.17, 5.51) <0.0001 |
LS=least-square; CI = confidence interval; TNSS = Total nasal symptom score; SNOT-22 = Sino-Nasal Outcome Test 22 Questionnaire; UPSIT = University of Pennsylvania Smell Identification Test; MID = minimal important difference.
Figure 1 Mean change from baseline in nasal congestion score and mean change from baseline in nasal polyp score by treatment group in nasal polyp study 1 and study 2
16
20
16
20
8
24
8
24
12
Week
12
Week
Baseline 4
Baseline 4
In a pre-specified pooled analysis of rescue treatment (systemic corticosteroids for >3 consecutive days or nasal polypectomy) during the 24-week treatment period, the proportion of patients requiring rescue treatment was lower in Xolair compared to placebo (2.3% versus 6.2%, respectively). The odds-ratio of having taken rescue treatment in Xolair compared to placebo was 0.38 (95% CI: 0.10, 1.49). There were no sino-nasal surgeries reported in either study.
The long-term efficacy and safety of Xolair in patients with CRSwNP who had participated in nasal polyp studies 1 and 2 was assessed in an open-label extension study. Efficacy data from this study suggest that clinical benefit provided at Week 24 was sustained through to Week 52. Safety data were overall consistent with the known safety profile of omalizumab.
Chronic spontaneous urticaria (CSU)
The efficacy and safety of Xolair were demonstrated in two randomised, placebo-controlled phase III studies (study 1 and 2) in patients with CSU who remained symptomatic despite H1 antihistamine therapy at the approved dose. A third study (study 3) primarily evaluated the safety of Xolair in patients with CSU who remained symptomatic despite treatment with H1 antihistamines at up to four times the approved dose and H2 antihistamine and/or LTRA treatment. The three studies enrolled 975 patients aged between 12 and 75 years (mean age 42.3 years; 39 patients 12–17 years, 54 patients >65 years; 259 males and 716 females). All patients were required to have inadequate symptom control, as assessed by a weekly urticaria activity score (UAS7, range 0–42) of >16, and a weekly itch severity score (which is a component of the UAS7; range 0–21) of >8 for the 7 days prior to randomisation, despite having used an antihistamine for at least 2 weeks beforehand.
In studies 1 and 2, patients had a mean weekly itch severity score of between 13.7 and 14.5 at baseline and a mean UAS7 score of 29.5 and 31.7 respectively. Patients in safety study 3 had a mean weekly itch severity score of 13.8 and a mean UAS7 score of 31.2 at baseline. Across all three studies, patients reported receiving on average 4 to 6 medications (including H1 antihistamines) for CSU symptoms prior to study enrollment. Patients received Xolair at 75 mg, 150 mg or 300 mg or placebo by subcutaneous injection every 4 weeks for 24 and 12 weeks in studies 1 and 2, respectively, and 300 mg or placebo by subcutaneous injection every 4 weeks for 24 weeks in study 3. All studies had a 16-week treatment-free follow-up period.
The primary endpoint was the change from baseline to week 12 in weekly itch severity score. Omalizumab at 300 mg reduced the weekly itch severity score by 8.55 to 9.77 (p <0.0001) compared to a reduction of 3.63 to 5.14 for placebo (see Table 9). Statistically significant results were further observed in the responder rates for UAS7<6 (at week 12) which were higher for the 300 mg treatment groups, ranging from 52–66% (p<0.0001) compared to 11–19% for the placebo groups, and complete response (UAS7=0) was achieved by 34–44% (p<0.0001) of patients treated with 300 mg compared to 5–9% of patients in the placebo groups. Patients in the 300 mg treatment groups achieved the highest mean proportion of angioedema-free days from week 4 to week 12, (91.0–96.1%; p<0.001) compared to the placebo groups (88.1–89.2%). Mean change from baseline to week 12 in the overall DLQI for the 300 mg treatment groups was greater (p<0.001) than for placebo showing an improvement ranging from 9.7–10.3 points compared to 5.1–6.1 points for the corresponding placebo groups.
Table 9 Change from baseline to week 12 in weekly itch severity score, studies 1, 2 and 3 (mITT population*)
| Placebo | Omalizumab 300 mg | |
| Study 1 | ||
| N | 80 | 81 |
| Mean (SD) | –3.63 (5.22) | –9.40 (5.73) |
| Difference in LS means vs. placebo1 | – | –5.80 |
| 95% CI for difference | – | –7.49,–4.10 |
| P-value vs. placebo2 | – | <0.0001 |
| Study 2 | ||
| N | 79 | 79 |
| Mean (SD) | –5.14 (5.58) | –9.77 (5.95) |
| Difference in LS means vs. placebo1 | – | –4.81 |
| 95% CI for difference | – | –6.49,–3.13 |
| P-value vs. placebo2 | – | <0.0001 |
| Study 3 | ||
| N | 83 | 252 |
| Mean (SD) | –4.01 (5.87) | –8.55 (6.01) |
| Difference in LS means vs. placebo1 | – | –4.52 |
| 95% CI for difference | – | –5.97, –3.08 |
| P-value vs. placebo2 | – | <0.0001 |
*Modified intent-to-treat (mITT) population: included all patients who were randomised and received at least one dose of study medication.
BOCF (Baseline Observation Carried Forward) was used to impute missing data.
-
1 The LS mean was estimated using an ANCOVA model. The strata were baseline weekly itch severity score (<13 vs. >13) and baseline weight (<80 kg vs. >80 kg).
-
2 p-value is derived from ANCOVA t-test.
Figure 2 shows the mean weekly itch severity score over time in study 1. The mean weekly itch severity scores significantly decreased with a maximum effect around week 12 that was sustained over the 24-week treatment period. The results were similar in study 3.
In all three studies the mean weekly itch severity score increased gradually during the 16-week treatment-free follow-up period, consistent with symptom re-occurrence. Mean values at the end of the follow-up period were similar to the placebo group, but lower than respective mean baseline values.
Figure 2 Mean weekly itch severity score over time, study 1 (mITT population)
Week
Omalizumab or placebo administered
BOCF=baseline observation carried forward; mITT=modified intention-to-treat population
Efficacy after 24 weeks of treatment
The magnitude of the efficacy outcomes observed at week 24 of treatment was comparable to that observed at week 12:
For 300 mg, in studies 1 and 3, the mean decrease from baseline in weekly itch severity score was 9.8 and 8.6, the proportion of patients with UAS7<6 was 61.7% and 55.6%, and the proportion of patients with complete response (UAS7=0) was 48.1% and 42.5%, respectively, (all p<0.0001, when compared to placebo).
There is limited clinical experience in re-treatment of patients with omalizumab.
Clinical trial data on adolescents (12 to 17 years) included a total of 39 patients, of whom 11 received the 300 mg dose. Results for the 300 mg are available for 9 patients at week 12 and 6 patients at week 24, and show a similar magnitude of response to omalizumab treatment compared to the adult population. Mean change from baseline in weekly itch severity score showed a reduction of 8.25 at week 12 and of 8.95 at week 24. The responder rates were: 33% at week 12 and 67% at week 24 for UAS7=0, and 56% at week 12 and 67% at week 24 for UAS7<6.
5.2 Pharmacokinetic properties
The pharmacokinetics of omalizumab have been studied in adult and adolescent patients with allergic asthma as well as in adult patients with CRSwNP, and adult and adolescent patients with CSU. The general pharmacokinetic characteristics of omalizumab are similar in these patient populations.
Absorption
After subcutaneous administration, omalizumab is absorbed with an average absolute bioavailability of 62%. Following a single subcutaneous dose in adult and adolescent patients with asthma or CSU, omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 6–8 days. In patients with asthma, following multiple doses of omalizumab, areas under the serum concentrationtime curve from Day 0 to Day 14 at steady state were up to 6-fold of those after the first dose.
The pharmacokinetics of omalizumab are linear at doses greater than 0.5 mg/kg. Following doses of 75 mg, 150 mg or 300 mg every 4 weeks in patients with CSU, trough serum concentrations of omalizumab increased proportionally with the dose level.
Administration of Xolair manufactured as a lyophilised or liquid formulation resulted in similar serum concentration-time profiles of omalizumab.
Distribution
In vitro , omalizumab forms complexes of limited size with IgE. Precipitating complexes and complexes larger than one million Daltons in molecular weight are not observed in vitro or in vivo. Based on population pharmacokinetics, distribution of omalizumab was similar in patients with allergic asthma and patients with CSU. The apparent volume of distribution in patients with asthma following subcutaneous administration was 78 ± 32 ml/kg.
Elimination
Clearance of omalizumab involves IgG clearance processes as well as clearance via specific binding and complex formation with its target ligand, IgE. Liver elimination of IgG includes degradation in the reticuloendothelial system and endothelial cells. Intact IgG is also excreted in bile. In asthma patients the omalizumab serum elimination half-life averaged 26 days, with apparent clearance averaging 2.4 ± 1.1 ml/kg/day. Doubling of body weight approximately doubled apparent clearance. In CSU patients, based on population pharmacokinetic simulations, omalizumab serum elimination half-life at steady state averaged 24 days and apparent clearance at steady state for a patient of 80 kg weight was 3.0 ml/kg/day.
Characteristics in patient populations
Age, Race/Ethnicity, Gender, Body Mass Index
Patients with allergic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP)
The population pharmacokinetics of omalizumab were analysed to evaluate the effects of demographic characteristics. Analyses of these limited data suggest that no dose adjustments are necessary for age (6–76 years for patients with allergic asthma; 18 to 75 years for patients with CRSwNP), race/ethnicity, gender or body mass index (see section 4.2).
Patients with CSU
The effects of demographic characteristics and other factors on omalizumab exposure were evaluated based on population pharmacokinetics. In addition, covariate effects were evaluated by analysing the relationship between omalizumab concentrations and clinical responses. These analyses suggest that no dose adjustments are necessary in patients with CSU for age (12–75 years), race/ethnicity, gender, body weight, body mass index, baseline IgE, anti-FcsRI autoantibodies or concomitant use of H2 antihistamines or LTRAs.
Renal and hepatic impairment
There are no pharmacokinetic or pharmacodynamic data in allergic asthma or CSU patients with renal or hepatic impairment (see sections 4.2 and 4.4).
5.3 Preclinical safety data
The safety of omalizumab has been studied in the cynomolgus monkey, since omalizumab binds to cynomolgus and human IgE with similar affinity. Antibodies to omalizumab were detected in some monkeys following repeated subcutaneous or intravenous administration. However, no apparent toxicity, such as immune complex-mediated disease or complement-dependent cytotoxicity, was seen. There was no evidence of an anaphylactic response due to mast-cell degranulation in cynomolgus monkeys.
Chronic administration of omalizumab at dose levels of up to 250 mg/kg (at least 14 times the highest recommended clinical dose in mg/kg according to the recommended dosing table) was well tolerated in non-human primates (both adult and juvenile animals), with the exception of a dose-related and agedependent decrease in blood platelets, with a greater sensitivity in juvenile animals. The serum concentration required to attain a 50% drop in platelets from baseline in adult cynomolgus monkeys was roughly 4– to 20-fold higher than anticipated maximum clinical serum concentrations. In addition, acute haemorrhage and inflammation were observed at injection sites in cynomolgus monkeys.
Formal carcinogenicity studies have not been conducted with omalizumab.
In reproduction studies in cynomolgus monkeys, subcutaneous doses up to 75 mg/kg per week (at least 8 times the highest recommended clinical dose in mg/kg over a 4-week period) did not elicit maternal toxicity, embryotoxicity or teratogenicity when administered throughout organogenesis and did not elicit adverse effects on foetal or neonatal growth when administered throughout late gestation, delivery and nursing.
Omalizumab is excreted in breast milk in cynomolgus monkeys. Milk levels of omalizumab were 0.15% of the maternal serum concentration.
6. PHARMACEUTICAL PARTICULARS6.1 List of excipients
Powder
Sucrose
L-histidine
L-histidine hydrochloride monohydrate
Polysorbate 20
Solvent
Water for injections
6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.
6.3 Shelf life
4 years.
After reconstitution
The chemical and physical stability of the reconstituted medicinal product have been demonstrated for 8 hours at 2°C to 8°C and for 4 hours at 30°C.
From a microbiological point of view, the medicinal product should be used immediately after reconstitution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 8 hours at 2°C to 8°C or 2 hours at 25°C.
6.4 Special precautions for storage
Store in a refrigerator (2°C – 8°C).
Do not freeze.
For storage conditions after reconstitution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
Powder vial: Clear, colourless type I glass vial with a butyl rubber stopper and blue flip-off seal.
Solvent ampoule: Clear, colourless type I glass ampoule containing 2 ml water for injections.
Pack containing 1 vial of powder and 1 ampoule of water for injections, and multipacks containing 4 (4 × 1) vials of powder and 4 (4 × 1) ampoules of water for injections or 10 (10 × 1) vials of powder and 10 (10 × 1) ampoules of water for injections.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
Xolair 150 mg powder for solution for injection is supplied in a single-use vial.
From a microbiological point of view, the medicinal product should be used immediately after reconstitution (see section 6.3).
The lyophilised medicinal product takes 15–20 minutes to dissolve, although in some cases it may take longer. The fully reconstituted medicinal product will appear clear to slightly opalescent, colourless to pale brownish-yellow and may have a few small bubbles or foam around the edge of the vial. Because of the viscosity of the reconstituted medicinal product care must be taken to withdraw all of the medicinal product from the vial before expelling any air or excess solution from the syringe in order to obtain the 1.2 ml.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
8. MARKETING AUTHORISATION NUMBER(S)
EU/1/05/319/002
EU/1/05/319/003
EU/1/05/319/004
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 25 October 2005
Date of latest renewal: 22 June 2015